Safety and Efficacy of Oral BT-11 in Crohn's Disease Patients With Moderate to Severe Disease

Key Inclusion Criteria: 1. Male and female subjects age 18 to 75 years, inclusive. 2. Diagnosis of CD for at least 6 weeks prior to screening 3. Moderate to severely active CD as defined by all of the following: * CDAI score of 220-450 * PRO-2 stool frequency (SF) ≥ 4 and/or abdominal pain (AP) ≥ 2 * SES-CD ≥ 6 ( ≥4 for isolated ileitis) scored by a blinded central reader Key Exclusion Criteria: 1. Participant has ulcerative colitis 2. Participant is at imminent risk of ileo-colectomy 3. Prior enrolment in the current study and had received study treatment.